Grŵp Strategaeth Meddyginiaethau Cymru Gyfan
All Wales Medicines Strategy Group

Final Appraisal Recommendation

Advice No: 2417 – November 2017

Pegvisomant (Somavert®) 10 mg, 15 mg, 20 mg, 25 mg and 30 mg powder and solvent for solution for injection

Resubmission by Pfizer Ltd

Recommendation of AWMSG

Pegvisomant (Somavert®) is recommended as an option for use within NHS Wales for the treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalise insulin-like growth factor-1 (IGF-1) concentrations or was not tolerated.

This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.

Additional note(s):

- AWMSG considered that pegvisomant (Somavert®) satisfied the AWMSG criteria for a medicine developed specifically for rare diseases as an ultra-orphan equivalent.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 3545), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue	Pfizer Ltd
Date of first issue	November 2017
Last reviewed	November 2020